Dogwood Therapeutics, Inc. (DWTX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Dogwood Therapeutics, Inc. (DWTX) has a cash flow conversion efficiency ratio of -0.042x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.27 Million) by net assets ($77.39 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market cap of Dogwood Therapeutics, Inc. for the company's overall valuation and market capitalisation.
Dogwood Therapeutics, Inc. - Cash Flow Conversion Efficiency Trend (2018–2024)
This chart illustrates how Dogwood Therapeutics, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View Dogwood Therapeutics, Inc. (DWTX) share price today for real-time trading data and today's change.
Dogwood Therapeutics, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Dogwood Therapeutics, Inc. ranked by their cash flow conversion efficiency. Review Dogwood Therapeutics, Inc. free cash flow to debt ratio to assess the company's free cash flow relative to its total liabilities.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Cornerstone OnDemand Inc
F:8CO
|
0.014x |
|
Heidelberger Beteiligungsholding AG
F:IPOK
|
N/A |
|
Singular Health Group Ltd
AU:SHG
|
-0.266x |
|
IFirma SA
WAR:IFI
|
0.126x |
|
Verbrec Ltd
AU:VBC
|
0.060x |
|
Newbury Street Acquisition Corp
NASDAQ:NBST
|
-0.025x |
|
Azimut Exploration Inc.
V:AZM
|
-0.037x |
|
Fodelia
HE:FODELIA
|
0.042x |
Annual Cash Flow Conversion Efficiency for Dogwood Therapeutics, Inc. (2018–2024)
The table below shows the annual cash flow conversion efficiency of Dogwood Therapeutics, Inc. from 2018 to 2024. Also see DWTX current and non-current assets for a full breakdown of the balance sheet.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $64.28 Million | $-8.79 Million | -0.137x | +89.31% |
| 2023-12-31 | $3.81 Million | $-4.87 Million | -1.279x | +18.26% |
| 2022-12-31 | $7.33 Million | $-11.47 Million | -1.565x | -44.67% |
| 2021-12-31 | $14.50 Million | $-15.69 Million | -1.082x | -731.66% |
| 2020-12-31 | $29.94 Million | $-3.90 Million | -0.130x | -130.73% |
| 2019-12-31 | $-4.94 Million | $-2.09 Million | 0.423x | -55.39% |
| 2018-12-31 | $-1.26 Million | $-1.20 Million | 0.949x | -- |
About Dogwood Therapeutics, Inc.
Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on the development of medicine to treat pain and fatigue-related disorders. Its lead product candidates include IMC-1, a fixed dose combination of famciclovir and celecoxib that has completed Phase 2b clinical trial to treat fibromyalgia; Halneuron, which is in Phase 2b clinical trial for the treatment of chemotherapy-… Read more